Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03280121 · ClinicalTrials.gov registry record · NA
Hernia Reduction Prior to Scheduled TIF Completion
A NA study, sponsored by EndoGastric Solutions.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT03280121: Clinical Trial NA study, sponsored by EndoGastric Solutions.
NCT03280121 is a NA study that was terminated before completion, run by EndoGastric Solutions. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03280121, a NA study, was terminated before completion, sponsored by EndoGastric Solutions.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
Hernia Reduction Prior to Scheduled TIF Completion using EsophyX ZR transoral device
Primary Outcome
Number of Participants with Normalization of Esophageal Acid Exposure. Normalization in esophageal acid exposure is defined by ≤ 5.3% of total time pH \< 4 in
Interventions
- DEVICE EsophyX ZR transoral device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-10-05 |
| Est. Completion | 2020-10-26 |
| Phase | NA |
Why NCT03280121 stopped before completion
NCT03280121 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which EsophyX ZR transoral device is the first listed.
NCT03280121 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03280121 about?
NCT03280121 is a clinical study titled "Hernia Reduction Prior to Scheduled TIF Completion". Hernia Reduction Prior to Scheduled TIF Completion using EsophyX ZR transoral device
What is the current status of trial NCT03280121?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2018-10-05. Estimated completion is 2020-10-26.
What interventions are being tested in trial NCT03280121?
The interventions under investigation include: EsophyX ZR transoral device (DEVICE).
Who is sponsoring clinical trial NCT03280121?
This trial is sponsored by EndoGastric Solutions, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03280121's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy